Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Marie Skłodowska-Curie Action · Running

TargetRNA Targeting RNA with small molecules

Coordinator
Universitetet I Bergen, Norway
Runs
1 September 2024 to 31 August 2028
Status
Running
EU funding
€4.3m
Total cost
—
Partners
17 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168667

What the project is doing

In the project's own words, from its summary on CORDIS.

RNA molecules play key roles in biological processes and diseases. An emerging avenue to develop innovative medicines is therefore to design small molecule drugs that bind to RNA and affect downstream biological functions. However, to advance this field of research, a new generation of scientists is needed that can further develop and ultimately master the challenging process of drug design applied to RNA. Therefore, the TargetRNA network aims to educate and nurture the next generation of scientists with cutting-edge interdisciplinary skills in the discovery and biological characterization of RNA modulators and thus generate fundamental knowledge on what drives affinity and specificity of small molecules binding to RNA.

The objective of TargetRNA is to develop compounds with antimicrobial activity through their interaction with RNA targets, and to use these to selectively reshape the human gut microbiome, an area with vast implications for medicine. Training through research activities, spanning from computational and medicinal chemistry over structural and molecular biology to microbiology and in vivo models, will be supplemented by an innovative training programme in specific and transferable skills for interdisciplinary drug discovery strategies to target RNA, including FAIR data principles, open science practices as well as responsible development and sustainable implementation of new innovations.

To achieve the ambitious research and training goals, the TargetRNA network unites leading scientists from 13 academic partners (8 beneficiaries, 5 associated) and 4 industry partners (1 beneficiary, 3 associated) based in 9 countries.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I BergenBergenNorwayCoordinator
Saverna Therapeutics AGBiel-BenkenSwitzerlandAssociatedpartner
Universitat BaselBaselSwitzerlandAssociatedpartner
CrystalsFirst GmbHMarburgGermanyAssociatedpartner
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric)BerlinGermanyAssociatedpartner
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Technische Hochschule MannheimMannheimGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Universite Cote D'azurNiceFranceParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyAssociatedpartner
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Stichting Radboud UniversiteitNijmegenNetherlandsParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Linkopings UniversitetLinkopingSwedenAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant
Malvern Panalytical LimitedMalvernUnited KingdomAssociatedpartner
Swansea UniversitySwanseaUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI